Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2026 | May 09, 2026 |
| JOHNSON & JOHNSONJNJ · Entity 2722 | Director · VP, Strategy & Growth · Member, Executive Committee | September 30, 2009 | October 02, 2009 |
| RTI SURGICAL, INC.RTIX · Entity 159205 | Director | March 08, 2019 | March 11, 2019 |
| Roka BioScience, Inc.ROKA · Entity 172682 | Director | June 28, 2017 | June 30, 2017 |
| SURGALIGN HOLDINGS, INC.SRGA · Entity 109633 | Director | August 15, 2022 | August 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2026 · Filed May 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,423 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 5,127 · Balance 84,423 F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
JOHNSON & JOHNSON
Report date September 30, 2009 · Filed October 02, 2009
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 57,353 |
Ending reported balance
After 2009-08-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2008-08-19 · Gift · Disposed 350 · Balance 57,703 F1: Gift Row 2 · 2009-08-25 · Gift · Disposed 350 · Balance 57,353 F1: Gift |
| CommonSEC Table I · non-derivative | IndirectJohnson & Johnson Stock Fund under the 401(k) Savings Plan | 8,784 |
Reported balance
After 2009-09-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2009-09-30 · Other · Acquired 76 · Balance 8,784 F2: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009). |
| CommonSEC Table I · non-derivative | IndirectAs custodian for Son under UTMA | 4,525 |
Reported balance
After 2009-08-19 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2009-08-19 · Gift · Acquired 350 · Balance 4,525 F1: Gift F4: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,886 |
Reported balance
After 2009-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2009-09-30 · Grant · Acquired 54 · Balance 6,886 F5: The Phantom Stock converts into common stock on a one-for-one basis. F6: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2009 at $61.15 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. |
| CommonSEC Table I · non-derivative | IndirectESOP under the 401(k) Savings Plan | 1,292 |
Reported balance
Holding disclosure · report date 2009-09-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,292 F3: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009). |
Filing footnotes · ownership attribution and instrument terms
F1: Gift
F2: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009).
F3: Shares held by ESOP under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009).
F4: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F5: The Phantom Stock converts into common stock on a one-for-one basis.
F6: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2009 at $61.15 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time.
RTI SURGICAL, INC.
Report date March 08, 2019 · Filed March 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 1
1 source rowRow 1 · 2019-03-08 · Disposition to issuer · Disposed 86,723 · Balance 0 F1: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc." F2: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger. F3: The reporting person will file a Form 4 reflecting his acquisition of the Issuer's securities in connection with the consummation of the Mergers. F4: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc."
F2: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger.
F3: The reporting person will file a Form 4 reflecting his acquisition of the Issuer's securities in connection with the consummation of the Mergers.
F4: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020.
Roka BioScience, Inc.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2027-06-27 | Direct | 3,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 3,000 · Balance 3,000 |
SURGALIGN HOLDINGS, INC.
Report date August 15, 2022 · Filed August 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,809 |
Reported balance
After 2022-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-08-15 · Grant · Acquired 22,857 · Balance 30,809 F1: Represents shares of restricted stock of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. F2: The total shares reported reflect 1:30 reverse stock split on May 17, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant.
F2: The total shares reported reflect 1:30 reverse stock split on May 17, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 9, 2026 01:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 5,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005055 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,423 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 09, 2025 Filed May 9, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 5,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004956 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,296 F1 · shares: These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2024 Filed May 9, 2024 23:42 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 4,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005897 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,732 F1 · shares: These restricted stock units were granted on May 8, 2024 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 12, 2023 Filed May 15, 2023 22:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005911 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,914 F1 · shares: These restricted stock units were granted on May 12, 2023 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:52 UTC | SURGALIGN HOLDINGS, INC. SRGA · Entity 109633 | GrantCommon Stock | 22,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046170 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,809 F1 · shares: Represents shares of restricted stock of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. F2 · balance_after: The total shares reported reflect 1:30 reverse stock split on May 17, 2022. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006588 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,111 F1 · shares: These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | PurchaseCommon Stock | 1,500 | $112.23 | $168,345.00 |
DisclosureSEC source: 0001225208-21-014149 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,811 Read SEC document |
| August 12, 2021 Filed Aug 13, 2021 15:47 UTC | SURGALIGN HOLDINGS, INC. SRGA · Entity 109633 | PurchaseCommon Stock | 55,000 | $0.95 | $52,250.00 |
DisclosureSEC source: 0001209191-21-051328 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,669 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9460 to $0.9481, inclusive. The reporting person undertakes to provide to Surgalign Holdings, Inc., any security holder of Surgalign Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4 footnote. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:32 UTC | SURGALIGN HOLDINGS, INC. SRGA · Entity 109633 | GrantCommon Stock | 57,803 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-031342 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,218 F1 · shares: Represents restricted stock units of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document |
| May 07, 2021 Filed Jul 2, 2021 20:56 UTC Amendment | SURGALIGN HOLDINGS, INC. SRGA · Entity 109633 | GrantCommon Stock | 72,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045041 · doc4a.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,669 F1 · shares: The Form 4 filed on 5/10/2021 representing restricted stock units of Surgalign Holdings, Inc. (the "Company") granted as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant erroneously reported 57,803 RSUs in column four. The purpose of this amendment is to correct the total underlying shares in columns four and five. Read SEC document |
| May 05, 2021 Filed May 7, 2021 22:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007760 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,311 F1 · shares: These restricted stock units were granted on May 5, 2021 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on the Issuer's Board. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionDirector Stock Option (Right to Acquire) · Derivative | 22,608 | $0.00 Strike: $20.76 | $0.00 |
DisclosureSEC source: 0001225208-21-001766 · doc4.xml · derivative · entry 3 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,608 shares Expires 2021-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,200 | $85.21 | $698,752.34 |
DisclosureSEC source: 0001225208-21-001766 · doc4.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,696 F1 · price: This transaction was executed in multiple trades at prices ranging from $85.1900 to $85.2800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 22,608 | $20.76 | $469,303.65 |
DisclosureSEC source: 0001225208-21-001766 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007362 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,096 F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| February 26, 2020 Filed Mar 2, 2020 18:44 UTC | SURGALIGN HOLDINGS, INC. RTIX · Entity 109633 | GrantCommon Stock | 24,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014373 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,415 F1 · shares: Represents shares of restricted stock of RTI Surgical Holdings, Inc. (the "Company") granted to Mr. Valeriani as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 22:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionDirector Stock Option (Right to Acquire) · Derivative | 4,000 | $0.00 Strike: $62.28 | $0.00 |
DisclosureSEC source: 0001225208-19-010795 · doc4.xml · derivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,536 Underlying: Common Stock · 4,000 shares Expires 2021-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 22:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,000 | $62.28 | $249,100.00 |
DisclosureSEC source: 0001225208-19-010795 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007862 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,995 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 13:46 UTC | RTI SURGICAL, INC. RTIX · Entity 159205 | Disposition to issuerCommon Stock | 86,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001100441-19-000010 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc." F2 · price: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger. F3 · price: The reporting person will file a Form 4 reflecting his acquisition of the Issuer's securities in connection with the consummation of the Mergers. F4 · price: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 17:52 UTC | SURGALIGN HOLDINGS, INC. RTIX · Entity 109633 | GrantCommon Stock | 86,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001760173-19-000024 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,723 F1 · price: On March 8, 2019, pursuant to the Master Transaction Agreement, by and among the Issuer, RTI Surgical, Inc., a Delaware corporation ("Old RTI"), PS Spine Holdco, LLC, a Delaware limited liability company (the "Member"), and Bears Merger Sub, Inc., a Delaware corporation (the "Merger Sub"): (a) the Merger Sub merged with and into Old RTI, with Old RTI surviving as a wholly-owned subsidiary of the Issuer (the "Merger"); (b) the Member contributed all of the issued and outstanding membership interests of Paradigm Spine, LLC, a Delaware limited liability company and wholly owned subsidiary of the Member, to the Issuer; and (c) the Issuer was renamed "RTI Surgical Holdings, Inc." F2 · price: Pursuant to the Master Transaction Agreement, at the effective time of the Merger: (a) each issued and outstanding share of common stock of Old RTI converted automatically into one share of the Issuer's common stock; (b) each issued and outstanding share of Series A Convertible Preferred Stock of Old RTI converted automatically into one share of the Issuer's Series A Convertible Preferred Stock; and (c) each stock option and restricted stock award granted by Old RTI converted into a stock option or restricted stock award, as applicable, of the Issuer with respect to an equivalent number of shares of the Issuer's common stock on the same terms and conditions as were applicable prior to the Closing. This report reflects the beneficial ownership of the reporting person at the time of the consummation of the Merger and does not include the securities of the Issuer acquired by the reporting person upon the consummation of the Merger. F3 · price: Total includes 21,322 shares of restricted stock that will vest on 2/26/2020. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 15:07 UTC | RTI SURGICAL, INC. RTIX · Entity 159205 | GrantCommon Stock | 21,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001100441-19-000003 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,723 F1 · shares: Represents shares of restricted stock of RTI Surgical, Inc.(the "Company") granted to Mr. Valeriani as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document |
| May 18, 2018 Filed May 22, 2018 23:43 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009756 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,672 F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 12:58 UTC | RTI SURGICAL, INC. RTIX · Entity 159205 | GrantCommon Stock | 17,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001100441-18-000002 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,401 F1 · shares: Represents shares of restricted stock of RTI Surgical, Inc. (the "Company") granted to Mr. Valeriani as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 10:36 UTC | RTI SURGICAL, INC. RTIX · Entity 159205 | PurchaseCommon Stock | 5,500 | $4.70 | $25,850.00 |
DisclosureSEC source: 0001100441-17-000017 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,754 Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 13:26 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001472343-17-000041 · wf-form4_149882919322582.xml · derivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-06-27 Read SEC document |
| May 16, 2017 Filed May 17, 2017 14:50 UTC | RTI SURGICAL, INC. RTIX · Entity 159205 | GrantCommon Stock | 16,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001100441-17-000014 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,254 F1 · shares: Represents shares of restricted stock of RTI Surgical, Inc. (the "Company") granted to Mr. Valeriani as part of the director compensation program of the Company, all of which will vest on the first anniversary of the date of grant. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009793 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,017 F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 04, 2017 Filed May 8, 2017 13:34 UTC | RTI SURGICAL, INC. RTIX · Entity 159205 | PurchaseCommon Stock | 5,500 | $4.60 | $25,300.00 |
DisclosureSEC source: 0001100441-17-000009 · primary_doc.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,770 Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 21:16 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | ConversionSeries A Convertible Preferred Stock · Derivative | 50 | $0.00 | $0.00 |
DisclosureSEC source: 0001472343-16-000239 · wf-form4_147881260050918.xml · derivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock, par value $0.001 per share · 7,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converted into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $7.00 per share resulting in his acquisition of 7,143 Common Shares. Common Shares disclosed reflect the October 11, 2016, 10 for 1 reverse stock split of the Company's Common Shares. The Series A Preferred Shares were adjusted proportionately and consequently, each share of Preferred Stock became convertible into approximately 143 shares of common stock. F2 · derivative.exercise_date: The Series A Preferred Shares automatically converted, upon receipt of Company shareholder approval and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Shares automatically converted, upon receipt of Company shareholder approval and had no expiration date. Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 21:16 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | ConversionCommon Stock, $0.001 par value per share | 7,143 | $7.00 | $50,001.00 |
DisclosureSEC source: 0001472343-16-000239 · wf-form4_147881260050918.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:31 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | PurchaseWarrant (right to buy) · Derivative | 71,429 | Not disclosed Strike: $0.70 | Not disclosed |
DisclosureSEC source: 0001472343-16-000196 · wf-form4_147466265192063.xml · derivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,429 Underlying: Common stock, par value $0.001 per share · 71,429 shares Expires 2016-09-21 F2 · price: The reporting person purchased 50 Series A Preferred Shares and five-year warrants to purchase 71,429 Common Shares at a purchase price of $1,000 per share pursuant to a private offering of the Company for a total of $50,000. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:31 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | PurchaseSeries A Convertible Preferred Stock · Derivative | 50 | Not disclosed Strike: $0.70 | Not disclosed |
DisclosureSEC source: 0001472343-16-000196 · wf-form4_147466265192063.xml · derivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50 Underlying: Common stock, par value $0.001 per share · 71,428 shares Expires not disclosed F2 · price: The reporting person purchased 50 Series A Preferred Shares and five-year warrants to purchase 71,429 Common Shares at a purchase price of $1,000 per share pursuant to a private offering of the Company for a total of $50,000. F1 · derivative.exercise_date: Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock and the lock up agreement dated September 21, 2016, reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converts, upon receipt by the Company of shareholder approval, into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $0.70 per share. The Series A Preferred Shares have no expiration date. F1 · derivative.expiration_date: Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock and the lock up agreement dated September 21, 2016, reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converts, upon receipt by the Company of shareholder approval, into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $0.70 per share. The Series A Preferred Shares have no expiration date. Read SEC document |
| September 30, 2009 Filed Oct 2, 2009 16:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 54 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000109 · edgar.xml · derivative · entry 6 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 Underlying: Common Stock · 54 shares Expires not disclosed F5 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F6 · derivative.exercise_date: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2009 at $61.15 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. F6 · derivative.expiration_date: Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on September 30, 2009 at $61.15 per share are to be settled in cash upon the Reporting Person's Retirement (with each Phantom Stock Unit representing the fair market value of one share of Common Stock on the settlement date). Alternatively, the cash value represented by the Phantom Stock Units may be transferred by the Reporting Person into an alternative investment account under the Plan at any time. Read SEC document |
| September 30, 2009 Filed Oct 2, 2009 16:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 76 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000109 · edgar.xml · nonDerivative · entry 3 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 8,784 F2 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009). F2 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (09/30/2009). Read SEC document |
| August 25, 2009 Filed Oct 2, 2009 16:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GiftCommon | 350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000109 · edgar.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,353 F1 · price: Gift Read SEC document |
| August 19, 2009 Filed Oct 2, 2009 16:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GiftCommon | 350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000109 · edgar.xml · nonDerivative · entry 5 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Indirect · As custodian for Son under UTMA Disclosed balance after: 4,525 F1 · price: Gift F4 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 30, 2009 Filed Jul 2, 2009 19:21 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 59 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000080 · edgar.xml · derivative · entry 5 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,832 Underlying: Common Stock · 59 shares Expires not disclosed F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F5 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2009 at $56.52 per share are to be settled in cash upon the Reporting Person's Retirement. F5 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on June 30, 2009 at $56.52 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| June 30, 2009 Filed Jul 2, 2009 19:21 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 241 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000080 · edgar.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 8,708 F1 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (06/30/2009). F1 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (06/30/2009). Read SEC document |
| March 31, 2009 Filed Apr 2, 2009 19:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 59 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000059 · edgar.xml · derivative · entry 5 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 59 shares Expires not disclosed F4 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F5 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2009 at $52.82 per share are to be settled in cash upon the Reporting Person's Retirement. F5 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on March 31, 2009 at $52.82 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| March 31, 2009 Filed Apr 2, 2009 19:33 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000059 · edgar.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 8,467 F1 · security: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (03/31/2009). F1 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (03/31/2009). Read SEC document |
| February 13, 2009 Filed Feb 17, 2009 23:53 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 7,713 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000043 · edgar.xml · derivative · entry 7 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,713 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each Restricted Share Unit, awarded under Issuer's Long-Term Incentive Plan on February 13, 2006, represents a contingent right to receive one share of Company Common Stock. F8 · derivative.expiration_date: Not applicable Read SEC document |
| February 13, 2009 Filed Feb 17, 2009 23:53 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon | 2,828 | $57.31 | $162,072.68 |
DisclosureSEC source: 0000200406-09-000043 · edgar.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,053 Read SEC document |
| February 13, 2009 Filed Feb 17, 2009 23:53 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon | 7,713 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000043 · edgar.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2009 Filed Feb 17, 2009 23:53 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPhantom Stock Units · Derivative | 1,944 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000043 · edgar.xml · derivative · entry 6 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,714 Underlying: Common Stock · 1,944 shares Expires not disclosed F5 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F6 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement. F6 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on February 12, 2009 at $56.97 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| February 09, 2009 Filed Feb 11, 2009 22:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 9,337 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000022 · edgar.xml · derivative · entry 7 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,337 Underlying: Common Stock · 9,337 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one share of Company Common Stock. F9 · derivative.expiration_date: The Restricted Share Units vest three years after date of grant. Read SEC document |
| February 09, 2009 Filed Feb 11, 2009 22:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Option (Right to Buy) · Derivative | 112,047 | $0.00 Strike: $58.33 | $0.00 |
DisclosureSEC source: 0000200406-09-000022 · edgar.xml · derivative · entry 6 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,047 Underlying: Common Stock · 112,047 shares Expires 2019-02-08 F7 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| January 30, 2009 Filed Feb 11, 2009 22:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000022 · edgar.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Indirect · Johnson & Johnson Stock Fund under the 401(k) Savings Plan Disclosed balance after: 8,124 F1 · price: Shares acquired in the Johnson & Johnson Stock Fund under Johnson & Johnson's 401(k) Savings Plan as of Plan's most recent reporting date (01/30/2009). Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 19:46 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherPhantom Stock Units · Derivative | 37 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-09-000004 · edgar.xml · derivative · entry 4 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,770 Underlying: Common Stock · 37 shares Expires not disclosed F4 · security: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2008 at $58.73 per share are to be settled in cash upon the Reporting Person's Retirement. F5 · derivative.exercise_price: The Phantom Stock converts into common stock on a one-for-one basis. F4 · derivative.exercise_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2008 at $58.73 per share are to be settled in cash upon the Reporting Person's Retirement. F4 · derivative.expiration_date: The Phantom Stock Units acquired under the Issuer's Executive Income Deferral Plan on December 31, 2008 at $58.73 per share are to be settled in cash upon the Reporting Person's Retirement. Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 19:46 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | OtherCommon | 77 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-09-000004 · edgar.xml · nonDerivative · entry 2 VALERIANI NICHOLAS J · CIK 0001263149 · Director · VP, Strategy & Growth · Member, Executive Committee 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) and ESOP Savings Plans Disclosed balance after: 9,301 F2 · security: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (12/31/2008). F2 · price: Shares acquired under Johnson & Johnson's 401(k) and ESOP Savings Plans as of Plans' most recent reporting date (12/31/2008). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.